恩替卡韦联合六味五灵片治疗慢性乙型肝炎41例疗效研究

Therapeutic efficacy of entecavir combined with Liuweiwuling tablets in 41 patients with chronic hepatits B

目的观察恩替卡韦联合六味五灵片治疗慢性乙型肝炎(chronic hepatitis B,CHB)的疗效和安全性。方法选择本院2010年7月—2011年7月门诊和住院CHB患者81例,将其分为联合用药组(41例)和对照组(40例)。给予联合用药组恩替卡韦联合六味五灵片治疗,给予对照组恩替卡韦治疗。治疗期间每月随访记录症状、体征和不良反应,治疗前及治疗第3、6、12个月分别检测HBsAg、HBeAg、HBV DNA、血常规和肝肾功能。结果联合用药组HBeAg转阴率、HBeAb转阳率、HBV DNA转阴率和ALT复常率均显著高于对照组,差异有统计学意义。2组均未出现过敏反应和肾损伤。联合用药组1例和对照组2例出现头晕和腹部不适等,均不影响治疗。结论恩替卡韦联合六味五灵片治疗CHB,能快速、强效地抑制HBV复制,安全性和耐受性良好,较单用恩替卡韦疗效好,但尚须今后进一步研究验证。

Objective To evaluate the efficacy and safety of entecavir combined with Liuweiwuling tablets in the treatment of chronic hepatitis B （CHB）. Methods A total of 81 CHB outpatients or hospitalized patients treated in our hospital from Jul. 2010 to Jul. 2011 were randomly divided into a combination group （n=41） and a control group （n=40）. The combination group was treated with entecavir combined with Liuweiwuling tablets, while the control group was given entecavir alone. Clinical symptoms, signs and adverse reactions were recorded monthly during the treatment, and HBsAg, HBeAg, HBV DNA, blood routine and liver-kidney function were detected before treatment and at 3-, 6- and 12-month of treatment, respectively. Results The HBeAg negative con-version rate, HBeAb positive conversion rate, HBV DNA negative conversion rate and ALT normalization rate of the combination group were significantly higher than those of the control group, and the differences between the two groups were significant. No aller-gic reaction and kidney injury were found in the two groups. Dizziness, abdominal discomfort and other adverse reactions occurred in one patient in the combination group and 2 patients in the control group, but had no effect on the treatment. Conclusions Ente-cavir combined with Liuweiwuling tablets can quickly and effectively suppress HBV replication in CHB patients. The combination medication is safe and well tolerated. The therapeutic efficacy of entecavir combined with Liuweiwuling tablets is better than that of entecavir alone, but needs further study to verify.